ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0125

The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases

Dionysis Nikolopoulos1, Konstantinos Charitidis2, Julius Lindblom2, Maria O Borghi3, Guillermo Barturen4, Marta Alarcon-Riquelme5, Lorenzo Beretta6 and Ioannis Parodis7, 1Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3IRCCS, Istituto Auxologico Italiano, Milan, Italy, 4Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 5Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 6Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 7Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, autoimmune diseases, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A peripheral type I interferon (IFN) signature distinguishes patients with pAPS from healthy individuals, but its broader molecular landscape compared with other autoimmune diseases remains unknown.

Methods: We analysed bulk RNA sequencing data from whole blood obtained from patients with pAPS (n=83), systemic lupus erythematosus (SLE; n=249), Sjögren’s disease (SjD; n=253), systemic sclerosis (SSc; n=247), and 497 matched healthy controls (HC) from the PRECISESADS project (NCT02890121). We applied supervised pathway enrichment analysis, unsupervised weighted gene co-expression network analysis (WGCNA), and deconvolution analysis to characterise the molecular profile of pAPS.

Results: A total of 85 upregulated and 10 downregulated differentially expressed genes (DEGs) were found in patients with pAPS compared with HC, including genes indicating an overall upregulation of type I and II IFN signalling, complement cascade, and coagulation in pAPS, coupled with differentially enriched neutrophil degranulation and monocyte chemotaxis pathways. However, only 15 of those genes were uniquely differentially expressed in patients with pAPS compared with those with any other of the investigated autoimmune diseases. The comparison between pAPS and SLE revealed 334 DEGs (71 up- and 263 downregulated). Enrichment analysis revealed downregulation of type I and II IFN signalling and complement cascade pathways in pAPS versus SLE. Moreover, type I and II IFN signalling was significantly downregulated in pAPS compared to SjD or even SSc. WGCNA identified 19 modules of co-expressed genes, with pAPS strongly linked only to upregulation of the “IFN” module compared to HC. However, the upregulation of the “IFN” gene module was more pronounced in SLE, SjD and SSc compared with pAPS, supporting a gradient in the upregulation of IFN-related genes across these diseases, as previously shown for APS-SLE1-2. Within pAPS, a history of miscarriages was positively associated with the “methylation” module, while thrombocytopenia was negatively associated with the “T cell” and “RNA processing” modules. Deconvolution analysis showed that patients with pAPS exhibited significant alterations in the proportions of neutrophils, NK, naïve T, and memory T, compared to HC. However, these differences were evident in patients with SLE compared to HC.

Conclusion: Patients with pAPS exhibit a distinct molecular profile within the spectrum of systemic autoimmune diseases, marked by a modest activation of interferon signalling. 1. Nikolopoulos D, et al. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Ann Rheum Dis. 2024 Aug 27;83(9):1132-43.2. Barturen G, et al. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis Rheumatol. 2021 Jun;73(6):1073-1085. doi: 10.1002/art.41610.


Disclosures: D. Nikolopoulos: None; K. Charitidis: None; J. Lindblom: None; M. Borghi: None; G. Barturen: None; M. Alarcon-Riquelme: None; L. Beretta: None; I. Parodis: Amgen, 5, 6, AstraZeneca, 5, 6, Aurinia, 5, BMS, 5, Eli Lilly, 5, F. Hoffman-La Roche Ltd, 5, 6, Gilead, 6, GSK, 5, 6, Janssen, 6, Novartis, 6, Otsuka, 5, 6, UCB, 2, 5.

To cite this abstract in AMA style:

Nikolopoulos D, Charitidis K, Lindblom J, Borghi M, Barturen G, Alarcon-Riquelme M, Beretta L, Parodis I. The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-ifn-signature-is-less-pronounces-in-primary-antiphospholipid-syndrome-compared-with-other-systemic-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-ifn-signature-is-less-pronounces-in-primary-antiphospholipid-syndrome-compared-with-other-systemic-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology